Swiss pharmaceutical maker Novartis AG has announced that they will stop selling the drug named ZELNORM out of fear it increases the risk of heart attack, stroke, or worsening heart chest pain that can later become a heart attack.
Novartis agreed to withdraw Zelnorm at the FDA's request, the agency said in a public health advisory.
Zelnorm, also known as tegaserod maleate, is a prescription medication which is approved for short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 with chronic constipation.
If you or a loved one have taken Zelnorm and suffered a heart attack, stroke or other cardiac related illness contact the Raphaelson Law Firm for a fee free comprehensive consultation. You may be entitled to damages.